Parkinson's patients who take 'magic mushrooms' see key benefits, study finds
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways
As Parkinson's cases continue to rise, the race is on for therapies to combat the effects of the disease — and researchers have pinpointed an unlikely source of relief.
Psilocybin, a psychedelic compound found in some mushrooms, has been found to improve mood, cognition and motor symptoms in Parkinson's patients, according to a new study from the University of California San Francisco (UCSF).
The substance, often referred to as "magic mushrooms," has previously been shown to alleviate depression and anxiety, which prompted the researchers to explore its potential for Parkinson's.
Psychedelic Retreat Reports 183% Spike In Bookings As Health Experts Cite 'Downside' Of Unregulated Use
People with the neurological movement disorder often suffer from "debilitating mood dysfunction" and don't tend to respond well to traditional antidepressants, according to a UCSF press release.
Psilocybin, a psychedelic compound found in some mushrooms, has been found to improve mood, cognition and motor symptoms in Parkinson's patients.
"Many people don't realize this, but mood symptoms in Parkinson's are linked to a faster physical decline," said lead study author Ellen Bradley, M.D., assistant professor and associate director of UCSF's Translational Psychedelic Research Program, in the release.
Read On The Fox News App
"And they are actually a stronger predictor of patients' quality of life with Parkinson's than their motor symptoms."
The small study included 12 people with mild to moderate Parkinson's disease. They ranged in age from 40 to 75. All had depression and/or anxiety.
Fda Rejects Mdma As Psychedelic-based Treatment For Mental Health, Ptsd
They all received a 10 mg-dose of psilocybin, then a 25 mg-dose two weeks later. To measure the effects, the participants met with a licensed therapist before and after receiving the medication.
At the one-week and one-month follow-ups, the patients reported "clinically significant improvements" not only in mood and cognition, but also motor function.
"These results are really encouraging," Bradley told Fox News Digital. "Depression and anxiety, which debilitate so many people with Parkinson's, improved significantly — and those improvements lasted for at least three months after patients took the drug."
Amir Inamdar, a pharmaceutical physician in the U.K. and chief medical officer at Cybin, noted that the improvement in motor symptoms was somewhat surprising.
"As the authors note, this could be because of the modulation of dopamine via psilocybin's effect on several serotonin receptor types." (Inamdar was not involved in the study.)
The most common side effects of psilocybin were anxiety, nausea, headache and elevated blood pressure, but none were serious enough to require medical care, according to the researchers.
People with the neurological movement disorder often suffer from "debilitating mood dysfunction" and don't tend to respond well to traditional antidepressants.
"Despite the reports of challenging experiences in a couple of participants, psilocybin seemed to be well-tolerated," Inamdar noted. "The side effects were consistent with what has been seen in other studies, with no precipitation/ exacerbation of psychotic symptoms."
The study, which was published in Neuropsychopharmacology, a Nature publication, was funded by an anonymous donor.
This was the first study to measure the effects of a psychedelic substance on patients with a neurodegenerative disease, according to USCF.
While this study was an "important first step," Bradley noted that the researchers can't draw conclusions from it, as it was a small pilot without a control group.
"We've now started a much larger trial designed to rigorously test if psilocybin is effective in Parkison's," she told Fox News Digital.
"We're also collecting multimodal biological data to understand how psilocybin works. That's critical not just for optimizing psilocybin treatments, but also for guiding development of next-generation psychedelics that are in the pipeline now and could be promising for people with Parkinson's."
Click Here To Sign Up For Our Health Newsletter
Bradley still recommends that Parkinson's patients approach psilocybin and other psychedelics with "a lot of caution."
"I wouldn't recommend to my patients with Parkinson's that they start using psilocybin," she clarified. "We're very, very early in this research, and we don't think these drugs will be safe for everyone with the illness."
This was the first study to measure the effects of a psychedelic substance on patients with a neurodegenerative disease, according to USCF.
"I hope that people continue to advocate for research so we can speed this process of identifying the right psychedelic treatment for the right patient at the right time."
Inamadar agreed that while the results are encouraging, the study was based on a small and limited sample.
For more Health articles, visit www.foxnews.com/health
"The study was also open-label, which lends itself to higher expectancy effects, though the improvements in mood and anxiety symptoms were still seen at three months," he added.
"Overall, [the] quite encouraging results warrant further investigation, certainly in trying to understand the mechanism behind improvement in motor symptoms."
Original article source: Parkinson's patients who take 'magic mushrooms' see key benefits, study finds
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Psychedelic Science 2025 Unveils Science, Studies & Trials Tracks Showcasing Next Generation in Brain Imaging, Clinical Trials, and Neuroplasticity
• Sessions cover the latest updates in psychedelic neuroscience, from psilocybin's effects on brain connectivity to trial design, clinical outcomes for PTSD, depression, addiction, and OCD, and the future of drug development through translational models and AI innovations • Speakers include globally renowned experts like Gabrielle Agin-Liebes, Ph.D., Michael Bogenschutz, M.D., Robin Carhart-Harris, Ph.D., Alan K. Davis, Ph.D., Gül Dölen, M.D., Ph.D., Ben Kelmendi, M.D., Franklin King, M.D., Amy Lehrner, Ph.D., Leslie Morland, Psy.D., David Nutt, Ph.D., Stephen Ross, M.D., Emmanuelle Schindler, M.D., Ph.D., and Nolan Williams, M.D. • Representing institutions include Columbia, CU Denver, Imperial College London, Johns Hopkins, LSU, Massachusetts General Hospital, NYU, Ohio State, Stanford, UC Berkeley, UCSD, UCSF, University of Alabama, University of New Mexico, University of Washington, and numerous VA centers DENVER, June 11, 2025 (GLOBE NEWSWIRE) -- Psychedelic Science 2025 (PS2025), the world's leading conference on psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), announced its Science, Studies, and Trials tracks—three of the conference's most anticipated and data-rich offerings. Taking place June 16–20, 2025, at the Colorado Convention Center in Denver, PS2025's research tracks will convene top clinical investigators, neuroscientists, biotech pioneers, and social scientists to present a comprehensive and cross-disciplinary view of this transformative field of study. At a time when the global mental health crisis continues to grow, PS2025 showcases therapeutic research using psychedelic compounds such as psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, and ketamine, which are being investigated as treatments for serious mental illnesses such as addiction, depression, PTSD, obsessive-compulsive disorder, as well as neurological conditions such as pain, Alzheimer's, Lyme Disease, and Parkinson's. Beyond clinical trials, PS2025 also offers the latest in psychedelic neuroscience, examining data from studies using new neuroimaging, cellular, and molecular research tools that deepen the understanding of the biological mechanisms underlying their remarkable effects. Social science research is also included that examines the usage, attitudes, and experiences of trial participants, psychedelic consumers, and the general public, providing important context for societal views about this rapidly growing field. 'With the science and understanding of psychedelic substances expanding exponentially in recent years, we're honored to welcome some of the world's top academic researchers to PS2025 so they can share this new knowledge with attendees from around the globe.'— Philippe Lucas, Ph.D., Director, Research & Safe Access, MAPS The Science, Studies, and Trials tracks will feature both senior research leaders as well as emerging voices from public and private universities throughout North America, as well as international institutions in the UK, Europe, and Latin America. This highly anticipated convergence allows scientists to engage deeply about hot topics, including durability of efficacy, safety and risk, placebo dynamics, the role of psychotherapy, transdiagnostic effects, precision psychiatry, biological mechanisms, novel compounds, and the role of government grants and private capital in innovation. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. Featured sessions in the Science, Studies, and Trials tracks include:20 Years of Human Neuroscience Research with PsychedelicsDavid Nutt, Ph.D., reflects on two decades of pioneering work using brain imaging and neuropharmacology to explore consciousness, depression, and psychedelic mechanisms of action. Psychedelic Frontiers at the National Institutes of Health: NIH-funded Studies, Research Opportunities, and PrioritiesJoin a conversation moderated by Stacy Fischer, M.D., featuring Michael Bogenschutz, M.D., and Patrick Finan, Ph.D., as they unpack the latest NIH-funded studies, explore future research opportunities, and discuss the evolving priorities shaping this rapidly growing field of psychedelic-assisted therapy. Frontiers in Psilocybin Research for OCD: Neural Mechanisms, Treatment Response, and Clinical ImplicationsIn a session moderated by Jamila Hokanson, M.D., Ben Kelmendi, M.D., and Terence Ching, Ph.D., explore cutting-edge research on psilocybin's neural effects, clinical outcomes, and its potential as a treatment for OCD. Studies of Psychedelic-Assisted Therapy for Addiction DisordersJoin a conversation with Matthew Johnson, Ph.D., and Rayyan Zafar, Ph.D., moderated by Peter Hendricks, Ph.D., for a discussion on the latest research into the use of psychedelics as tools to treat addiction. This session will explore emerging evidence, clinical insights, and the challenges and promises of integrating psychedelic-assisted therapy into addiction treatment frameworks. Psychedelic Therapy for Military Veterans: A New Paradigm of Healing the Wounds of WarModerated by Chris Stauffer, M.D., and featuring Allie Kaigle, PharmD, BCPP, Amy Lehrner, Ph.D., and Leslie Morland, Psy.D., this session examines how psychedelic-assisted therapies are reshaping the landscape of care for Veterans grappling with PTSD, depression, and moral injury. By combining cutting-edge research with lived experience, these experts reveal how these innovative therapies can unlock hope, resilience, and lasting healing for those who have Outcomes from a Trial of Psilocybin-Assisted Therapy for Major Depressive DisorderIn this presentation, Alan K. Davis, Ph.D., shares groundbreaking findings from a long-term follow-up study examining the sustained effects of psilocybin-assisted therapy for individuals with major depressive disorder and what these results mean for the future of psychedelic treatments in mental health care. Ayahuasca: Bridging Molecular and Clinical Insights – A Multidisciplinary PanelDráulio Araújo, Ph.D., moderates a conversation with Fernanda Palhano-Fontes, Ph.D., Marcelo Falchi Parra Carvalho Silva, M.D., and Marcelo Leite, Ph.D., on the multifaceted world of ayahuasca through a unique convergence of molecular research, clinical practice, and traditional wisdom. The conversation offers insights into ayahuasca's molecular mechanisms and its applications in healing trauma and supporting personal growth. Developing Ibogaine for Opioid Use Disorder: Bridging Science, Public Benefit, and Sacred RootsSusan Ousterman moderates a conversation with Jeremy Weate, Ph.D., Ryan Rich, and Peter Hendricks, Ph.D., on the journey of ibogaine from traditional medicine to modern addiction therapy. Together, they'll explore clinical advancements, regulatory challenges, and how to ethically integrate indigenous knowledge and practices to address the opioid epidemic. Improving Standardization and Reducing Bias in Psychedelic Drug Development Trials Using an AI-Enabled PlatformJennifer Tippett, Psy.D., and Danielle Schlosser, Ph.D., discuss how artificial intelligence can transform psychedelic research by improving standardization, reducing bias, and enhancing data quality in clinical trials. Discover how this innovative approach is shaping the next generation of rigorous, ethical, and effective psychedelic drug development. The Potential for Psychedelic-Assisted Therapy in Conflict-Affected Populations: Ukraine and the BalkansModerated by Tadeusz Hawrot and featuring Oksana Gryshchenko, Elise Wilson, Zina Besirevic, Ph.D., and Galyna Pidpruzhnykova, Ph.D., this panel explores how psychedelic-assisted therapies might offer pathways to healing for individuals and communities affected by war and Differences in Therapeutic Outcomes Between Synthetic Psilocybin and Whole Psilocybe Mushrooms: A Qualitative StudyJoin Pamela Kryskow, M.D., and Joseph La Torre, Ph.D., as they present their qualitative study exploring the participants' lived experiences and perceptions, offering a deeper understanding of how these distinct forms of psilocybin influence healing, integration, and personal transformation. The Unique Challenges and Potential for Studying Psychedelic-Assisted Therapy for Palestinians and Jews in IsraelModerated by Keren Tzarfaty, Ph.D., MFT, and featuring Adar Avnon, Sidi Ronen, Ph.D., and Clinical Psychologist Wasim Biroumi, this session dives into the promise and complexities of researching psychedelic-assisted therapy in the unique socio-political landscape of Israel. The panel will discuss how shared trauma and cultural dynamics shape therapeutic approaches and the role psychedelics may play in fostering healing, understanding, and resilience across Outcomes from Yale's Real-World Psilocybin Trial: Connecticut-Funded Pioneering Psychedelic Therapy Program and Insights from Other State InitiativesJesse MacLachlan and Gabrielle Agin-Liebes, Ph.D., share findings from Yale's groundbreaking psilocybin trial, the first state-funded psychedelic therapy program in the U.S. This session will examine the transdiagnostic benefits observed in real-world settings and highlight key insights from Connecticut's initiative alongside other state-led programs shaping the future of psychedelic-assisted Critical Periods and Cephalopods: A Conversation with Neuroscientist Dr. Gül DölenJoin Gül Dölen, M.D., Ph.D., and Amy Emerson for a fascinating conversation that spans critical periods in brain development and the remarkable learning abilities of cephalopods. This session will illuminate the connections between these insights and the potential of psychedelics to re-open windows of plasticity in the adult brain. Listening to Lead: How a Community-Informed Psilocybin Study is Guiding New Mexico's Regulated ModelCrystal Romero, Janus Herrera, Dara Menashi, Ph.D., Larry Leeman, M.D., and Hanifa Nayo Washington (moderator) explore how New Mexico's historic Senate Bill 219 is paving the way for the nation's first state-regulated medical psilocybin program. This panel spotlights the community-informed pilot study by the Psychedelic Health Equity Initiative (PHEI), designed to center equity, accessibility, and culturally attuned care for underserved communities. Expanding the Lens: Mechanisms, Models & Modes - Transdiagnostic Potential of Psychedelic MedicinesJoin Charles Nichols, Ph.D., and Robin Carhart-Harris, Ph.D., as they unpack the unique mechanisms and models of action that position psychedelics as potential transdiagnostic treatments by addressing shared root causes across conditions. Treating Care Providers and Long COVID with Psychedelic-Assisted TherapyAnthony Back, M.D., moderates a vital discussion with Lawrence Purpura, M.D., Ph.D., Benjamin Lewis, M.D., Kush Bhatt, M.D., and Saleena Subaiya, M.D., on the emerging promise of psychedelic-assisted therapy to help those suffering from long COVID and the burnout experienced by care providers. This session will share clinical updates, innovative approaches, and new possibilities for fostering healing for those on the front lines of care. A Machine Learning Perspective on Psychedelics and PsychopathologyArthur Juliani, Ph.D., shares how artificial intelligence is revolutionizing clinical trial design, protocol optimization, and predictive modeling for psychedelic studies. From Rodents to Humans: Unlocking the Science of Psychedelic-Induced NeuroplasticityModerated by Lindsay Cameron, Ph.D., and featuring Manesh Girn, Ph.D., Max Vargas, Ph.D., and Neil Savalia, M.D./Ph.D(c), this session investigates the limitations of preclinical models in capturing the complexity of human psychedelic experiences and what these challenges mean for the future of psychedelic drug development. Psilocybin Desynchronizes the Human BrainJoin Joshua Siegel, M.D., Ph.D., as he delves into cutting-edge research exploring how psilocybin disrupts established patterns of brain connectivity – unpacking how these transient states of neural desynchronization might illuminate new pathways for therapeutic breakthroughs, and revealing the brain's remarkable flexibility and potential for healing. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
KFSHRC First in the Middle East to Implant AI-Powered Brain-Sensing Device for Treating Neurological Disorders
RIYADH, Saudi Arabia, June 11, 2025 (GLOBE NEWSWIRE) -- In a landmark medical achievement, King Faisal Specialist Hospital & Research Centre (KFSHRC) has become the first institution in the Middle East to successfully implant an AI-powered brain-sensing device designed for the treatment of complex neurological disorders. The breakthrough ushers in a new era of real-time, adaptive neuromodulation therapy, offering renewed hope for patients suffering from Parkinson's disease, epilepsy, and other movement disorders. The device utilizes artificial intelligence to continuously monitor the brain's electrical activity, identifying abnormal neural signals and delivering precisely targeted electrical impulses to restore neurological balance. Powered by a closed-loop system, the device automatically adjusts stimulation in real time based on the patient's brain activity, enabling highly responsive, personalized therapy and consistent symptom control throughout the day. The minimally invasive procedure, typically completed within three to five hours, has shown the potential to reduce patients' reliance on medication by as much as 50%. This cuts down detrimental side effects and enhances patients' autonomy and quality of life. Initial outcomes suggest rapid post-operative recovery and tangible improvements in symptom control within weeks. This breakthrough reflects the leadership and clinical excellence of KFSHRC's Neuroscience Centre of Excellence, which provides comprehensive, multidisciplinary care for adult and paediatric neurological cases. The Center leads the region in deep brain stimulation (DBS) for movement disorders, stereotactic EEG for epilepsy, and AI-based diagnostics for cognitive conditions and autism. Through continuous innovation and a patient-centred approach, it is redefining regional standards in neuroscience and setting new benchmarks in precision brain health. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@ A photo accompanying this announcement is available at
Yahoo
5 hours ago
- Yahoo
A Study Says Gray Hair May Be Reversible
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A study links graying hair to stem cells getting stuck, unable to color new hair growth. Stem cells travel back and forth within compartments, but when they get stuck in one compartment, they cannot regenerate into pigment cells. Restoring mobility of the cells could allow the continuation of pigment production, eliminating graying hair. If only our pesky stem cells didn't get stuck in place after a while, maybe we wouldn't have gray hair. Really. In a study published in the journal Nature, researchers from New York University's Grossman School of Medicine revealed how stuck melanocyte stem cells (McSCs) can't make the protein needed to pigment hair, potentially explaining gray hair. Using mice as the research subjects, the team found that McSCs travel between compartments of developing hair follicles in a healthy situation. The differing compartments allow the McSCs to mature and pick up the protein that can regenerate into pigment cells and continually color hair as it grows. These McSCs shift back and forth between maturity levels over time as they continually move between the compartments, a unique aspect of the McSCs. But in some cases, the McSCs can get stuck in the hair follicle bulge compartment and become unable to move back to the germ compartment, where the WNT proteins encourage the cells to regenerate into pigment cells. Getting stuck means no pigment cells, which means gray hair. 'It is the loss of chameleon-like function in melanocyte stems cells that may be responsible for graying and loss of hair color,' Mayumi Ito, study senior investigator and professor in the Ronald O. Perelman Department of Dermatology and Department of Cell Biology at NYU Langone Health, says in a news release. 'These findings suggest that melanocyte stem cell motility and reversible differentiation are key to keeping hair healthy and colored.' Basically, if the McSCs can keep moving—or, if they get stuck, we can somehow prod them to get going again—we should expect more colorful heads of hair the world over. 'Our study adds to our basic understanding of how melanocyte stem cells work to color hair,' Qi Sun, postdoctoral fellow at NYU Langone Health, says in the release. 'The newfound mechanisms raise the possibility that the same fixed positioning of melanocyte stem cells may exist in humans. If so, it presents a potential pathway for reversing or preventing the graying of human hair by helping jammed cells to move again between developing hair follicle compartments.' The McSCs focus on pigment-making, and are different from cells responsible for hair growth, Sun says, so hair can to continue growing even without pigment. The NYU study showed that as the hair regrowth process aged, the number of McSC's lodged in the follicle bulge continued to increase. At some points, this non-pigment producing follicle bulge contains roughly 50 percent of all McSCs. The McSCs that remained mobile retained their ability to produce pigment, but with the ever-shifting requirements of McSCs breaking down over time, the rise of gray hair coincided with aging. And while stress has also been associated with graying hair, unrelated Harvard research says that stress simply increases the hair regrowth pattern, speeding up the aging process for hair follicles. 'For unknown reasons, the melanocyte stem cell system fails earlier than other adult stem cell populations, which leads to hair graying in most humans and mice,' according to the NYU study. The next step for the NYU team involves looking at how we can get McSCs, once stuck, moving again. Because once they move, they create pigment. And that could mean the end of gray. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?